

Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? | zacks.com • |
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment | proactiveinvestors.com • |
BioCryst to Present at Upcoming Investor Conferences | globenewswire.com • |
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript | seekingalpha.com • |
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates | zacks.com • |
BioCryst to Report Second Quarter 2023 Financial Results on August 3 | globenewswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-11-07 | 2023-09 | -0.25 | N/A | N/A | N/A |
2023-08-03 | 2023-06 | -0.25 | -0.24 | 0.01 | 4.00% |
2023-05-03 | 2023-03 | -0.3 | -0.28 | 0.02 | 6.67% |
2023-02-21 | 2022-12 | -0.19 | -0.38 | -0.19 | -100.00% |
2022-11-01 | 2022-09 | -0.32 | -0.23 | 0.09 | 28.13% |
2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-13 | B of A Securities | Upgrade | Neutral | Buy |
2023-05-04 | RBC Capital | Upgrade | Sector Perform | |
2023-05-04 | Needham | Upgrade | Buy | |
2023-04-20 | Evercore ISI Group | Upgrade | Outperform | |
2023-04-20 | Needham | Upgrade | Buy | |
2023-03-14 | RBC Capital | Upgrade | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-06-12 | ABERCROMBIE GEORGE B | Director | 29.61K | Stock Award(Grant) |
2023-06-12 | ASELAGE STEPHEN J | Director | 63.34K | Stock Award(Grant) |
2023-06-12 | GALSON STEVEN K | Director | 29.61K | Stock Award(Grant) |
2023-06-12 | HEGGIE THERESA | Director | 49.11K | Stock Award(Grant) |
2023-06-13 | HUTSON NANCY J | Director | 81.82K | Sale |
2023-06-12 | LEE KENNETH B. | Director | 68.86K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-03-30 | Blackrock Inc. | 14.82M | 108.96M | 7.85% |
2023-03-30 | Vanguard Group, Inc. (The) | 14.83M | 108.97M | 7.85% |
2023-03-30 | Baker Brothers Advisors, LLC | 12.71M | 93.42M | 6.73% |
2023-03-30 | State Street Corporation | 11.39M | 83.71M | 6.03% |
2023-03-30 | Avoro Capital Advisors LLC | 10.42M | 76.59M | 5.52% |
2023-03-30 | Pictet Asset Management SA | 5.62M | 41.30M | 2.97% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-02-27 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 6.52M | 47.92M | 3.46% |
2022-12-30 | Vanguard Total Stock Market Index Fund | 5.65M | 41.54M | 3.00% |
2023-02-27 | iShares Russell 2000 ETF | 4.10M | 30.13M | 2.18% |
2023-02-27 | Fidelity Select Portfolios - Biotechnology | 2.69M | 19.79M | 1.43% |
2022-12-30 | Vanguard Extended Market Index Fund | 2.52M | 18.51M | 1.34% |
2022-12-30 | Vanguard Small-Cap Index Fund | 2.40M | 17.65M | 1.27% |
Dividend | Date |
---|---|
0 | 2014-06-11 |
0 | 2014-06-05 |
0 | 2014-05-20 |
0 | 2014-05-16 |
0 | 2014-04-02 |
-
-
$BCRX I guess we can forget the PLUS huh Jon ?
-
-
$BCRX MartinPlante is delusional he’s a mixed up sea turtle SCAM
-
$BCRX 15 SHARES Pre mkt.
-
$BCRX Marango give it up buddy spew your loser garbage somewhere else move on!
-
$BCRX Glad I’ve got a $1.92 avg.
-
$BCRX this could be the next CCXI….then mabe NOT!
-
$BCRX News flash we are up $3.03 from 3/15/2018 wow!
-
$BCRX I mean sell some more.
-
$BCRX 9 scripts …1.25 scripts per continent Boy we are tearing um up better buy some more shares
-
$BCRX Maphere folded his tent and moved to CLSD a few weeks back
-
$BCRX It’s ashamed this board is turning into a nursery play room
-
$BCRX Another day of baby Joey
-
$BCRX @Joey Go away you lost. Take it like a man move on get off the lot see u later!
-
$BCRX Man oh man holding since 2019 through ups and downs kept the faith but it’s getting hard we are sitting here on a day we should be running and the shorts are sticking it to us what to do
-
$BCRX Let’s get um Horned Frogs
-
-
$BCRX Well we’ve got us a new cry baby
-
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
proactiveinvestors.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Second Quarter 2023 Financial Results on August 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst to Report First Quarter 2023 Financial Results on May 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst: Good Candidate For Buyout, But Not For Anything Else
seekingalpha.com • -
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
globenewswire.com • -
Pharmaceutical Stock Sinks on Sales Forecast
schaeffersresearch.com • -
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
globenewswire.com • -
BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
seekingalpha.com • -
BCRX Stock Sinks as BioCryst Discontinues Drug Development
investorplace.com • -
BioCryst to discontinue development of drug
marketwatch.com • -
BioCryst to Present at JMP Securities Hematology & Oncology Summit
globenewswire.com • -
3 Biotechnology stocks under 10 dollars to buy now
thedogofwallstreet.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Third Quarter 2022 Financial Results on November 1
globenewswire.com • -
3 Biotech Stocks to Buy Now for Extraordinary Gains
investorplace.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com •